AbbVie's rapidly expanding Humira successor, SKYRIZI, is
already achieving impressive sales growth. This IL-23 inhibitor is
set to capture an even greater portion of Humira's diminishing
market share with its crucial expansion into treating ulcerative
colitis.
LAS
VEGAS, July 15, 2024 /PRNewswire/ -- Ulcerative
colitis is an idiopathic inflammatory bowel disease affecting ~1.5
million patients in the US and with an unknown exact cause. It
affects the colonic mucosa and is clinically characterized by
diarrhea, stomach discomfort, pain, and hematochezia. The disease's
extent varies, affecting either the rectum, the splenic flexure of
the left side of the colon, or the whole of the rectum and
bowel.
As per DelveInsight analysis, the total ulcerative colitis
diagnosed prevalent cases in the 7MM comprised approximately 3
million cases in 2023 and are projected to increase by 2034.
Per analyst estimates, approximately 60% of cases accounted
for moderate to severe cases of ulcerative colitis among the
7MM.
The current treatments for ulcerative colitis depend on the
severity of the disease and are broadly divided into six classes,
comprising conventional therapies, Anti-TNFs, Anti-integrin
agents, IL-12/IL-23 dual inhibitors, S1P-receptor modulators, and
JAK inhibitors.
The emergence of several mechanisms of action, like LANCL2
protein stimulators, miR-124 enhancers, tumor necrosis factor
(TNF)-like ligand 1A inhibitors, toll-like receptor 9 agonists,
and others will be expanding the treatment landscape of ulcerative
colitis.
There have been significant advancements in treating ulcerative
colitis over the years. However, safety remains a major challenge.
The lack of a safer and curative treatment option severely impacts
patients' quality of life and daily activities. While current
treatments are effective for some patients with ulcerative colitis,
others need multiple lines of therapy, indicating a need for
alternative treatments to achieve disease control. Several major
pharmaceutical companies are collaborating to develop new solutions
to address these issues.
Learn more about the FDA-approved ulcerative colitis drugs @
Drugs for Ulcerative Colitis Treatment
A few FDA-approved drugs for ulcerative colitis treatment
include SIMPONI (Janssen Pharmaceuticals), ENTYVIO (Takeda
Pharmaceuticals), OMVOH (Eli Lilly) VELSIPITY (Arena
Pharmaceuticals/Pfizer), and SKYRIZI (AbbVie).
SIMPONI is a human monoclonal antibody that targets and
neutralizes excess tumor necrosis factor (TNF)-alpha, a protein
associated with inflammation and tissue damage in chronic
inflammatory diseases. It is the first subcutaneous anti-TNF-alpha
treatment administered every four weeks as maintenance therapy for
ulcerative colitis. Approved for treating moderately to severely
active ulcerative colitis in adults, SIMPONI is also being
evaluated in ongoing trials for pediatric patients with the same
condition.
Vedolizumab is a humanized monoclonal antibody that
targets and inhibits the alpha 4 beta 7 integrin, preventing it
from binding to the intestinal mucosal addressing cell
adhesion molecule 1 (MAdCAM-1). This integrin is found in a subset
of circulating white blood cells that play a role in the
inflammatory processes of ulcerative colitis and Crohn's disease.
By blocking the alpha 4 beta 7 integrin, vedolizumab may reduce the
infiltration of these white blood cells into gut tissues.
It is currently approved as an IV and SC formulation for the
treatment of moderately to severely active ulcerative colitis in
adults who have not responded to, lost response to, or were
intolerant to conventional therapy or a tumor necrosis factor-alpha
(TNFα) antagonist.
VELSIPITY (Etrasimod) is an innovative, once-daily
oral medication that acts as a highly selective modulator of the
sphingosine 1-phosphate (S1P) receptor. Discovered by Arena,
it is designed for optimized interaction with S1P receptors 1, 4,
and 5, potentially offering better efficacy and safety. Etrasimod
targets specific immune cells both systemically and locally and has
the potential to treat various immune-mediated inflammatory
diseases, such as Crohn's disease and ulcerative colitis.
It is currently approved by the FDA and EMA for adults with
moderately to severely active ulcerative colitis who have not
responded adequately, lost response, or were intolerant to
conventional or advanced therapies.
Recently, on 18 June 2024, the FDA
approved SKYRIZI for treating adult patients with moderately to
severely active ulcerative colitis. This approval extends the
drug's reach to approximately 1 million US patients and makes
SKYRIZI the first IL-23 inhibitor approved for both UC and Crohn's
disease, the two types of inflammatory bowel disease (IBD).
After a 12-week induction period, patients can self-administer
the medication at home using an on-body injector device, which
AbbVie's press release describes as "designed with patients in
mind." The device attaches to the body and delivers the medication
in about five minutes.
Since its approval for Crohn's in 2022, Skyrizi has emerged as a
strong competitor to Johnson & Johnson's blockbuster drug
STELARA in the IBD market. The AbbVie medication has captured a
"significant share" of STELARA's sales.
To know more about ulcerative colitis treatment options, visit @
New Treatment for Ulcerative Colitis
The ulcerative colitis market is crowded with so many companies
including Arena Pharmaceuticals, Pfizer, Abivax, Reistone
Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim,
Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck,
Mesoblast, and others are running clinical trials to improve
the treatment space. The ulcerative colitis pipeline possesses
potential drugs in mid-stage developments to be launched
shortly.
Some of the promising drugs in the pipeline include TREMFYA,
ABX464, BT-11 (Omilancor), PRA023, Remestemcel-L, SHR0302
(Ivarmacitinib), and others that hold the potential to create a
significant positive shift in the ulcerative colitis market
size.
Discover which therapies are expected to grab major ulcerative
colitis market share @ Ulcerative Colitis Market Report
TREMFYA (guselkumab) is a human monoclonal antibody
targeting the p19 subunit of interleukin (IL)-23, created by
Janssen. IL-23 plays a crucial role in the pathogenesis of
inflammatory diseases like ulcerative colitis and Crohn's disease.
TREMFYA, an IL-23 inhibitor, is a human immunoglobulin G1 lambda
(IgG1λ) monoclonal antibody, produced in a mammalian cell line
using recombinant DNA technology. It specifically binds to the p19
subunit of IL-23 and blocks its interaction with the IL-23
receptor.
In May 2024, Johnson & Johnson
released the initial data from the Phase III QUASAR maintenance
study in ulcerative colitis, which achieved its primary endpoint
and all major secondary endpoints, including highly statistically
significant rates of endoscopic remission. Based on these findings,
the company has submitted a supplemental Biologics License
Application (sBLA) to the FDA.
SHR0302, developed by Reistone Biopharma, is an
innovative and potent oral JAK1 inhibitor aimed at treating
inflammatory bowel diseases like ulcerative colitis and Crohn's
disease. Due to its selectivity for JAK1, it may offer a safer and
more effective alternative to pan-JAK inhibitors. Ongoing long-term
clinical studies are investigating whether JAK1 selectivity can
minimize hematological side effects associated with JAK2
inhibition, aiming to confirm a favorable risk-benefit profile
(Reistone Biopharma, 2021a).
SHR0302 is currently being tested in a Phase III clinical trial
(NCT05181137) for the treatment of moderate to severe ulcerative
colitis in adults.
Discover more about drugs for ulcerative colitis in
development @ Ulcerative Colitis Clinical Trials
The anticipated launch of these emerging therapies for
ulcerative colitis are poised to transform the market
landscape in the coming years. As these cutting-edge therapies
continue to mature and gain regulatory approval, they are expected
to reshape the ulcerative colitis market landscape, offering
new standards of care and unlocking opportunities for medical
innovation and economic growth.
DelveInsight estimates that the market size for ulcerative
colitis is expected to grow from USD 8.4
billion in 2023 with a significant CAGR by 2034. This
growth can be attributed to the introduction of upcoming therapies
and the rising prevalence of the disease. The anticipated launch of
these therapies is also expected to attract new entrants to the
ulcerative colitis market, resulting in increased competition and
innovation.
DelveInsight's latest published market report titled as
Ulcerative Colitis Market Insight, Epidemiology, and Market
Forecast – 2034 will help you to discover which market
leader is going to capture the largest market share. The report
provides comprehensive insights into the ulcerative colitis
country-specific treatment guidelines, patient pool analysis, and
epidemiology forecast to help understand the key opportunities and
assess the market's underlying potential. The ulcerative
colitis market report proffers epidemiological analysis
for the study period 2020–2034 in the 7MM segmented into:
- Total Diagnosed Prevalent Cases of Ulcerative Colitis
- Age-specific Cases of Ulcerative Colitis
- Severity-specific Cases of Ulcerative Colitis
- Total Treated Patients of Ulcerative Colitis
The report provides an edge while developing business strategies
by understanding trends shaping and driving the 7MM ulcerative
colitis market. Highlights include:
- 11-year Forecast
- 7MM Analysis
- Epidemiology-based Market Forecasting
- Historical and Forecasted Market Analysis upto 2034
- Emerging Drug Market Uptake
- Peak Sales Analysis
- Key Cross Competition Analysis
- Industry Expert's Opinion
- Access and Reimbursement
Download this ulcerative colitis market report to assess
the epidemiology forecasts, understand the patient journeys, know
KOLs' opinions about the upcoming treatment paradigms, and
determine the factors contributing to the shift in the ulcerative
colitis market. Also, stay abreast of the mitigating factors
to improve your market position in the ulcerative
colitis therapeutic space.
Related Reports
Ulcerative Colitis Epidemiology Forecast
Ulcerative Colitis Epidemiology Forecast –
2032 report delivers an in-depth understanding of the
disease, historical and forecasted ulcerative
colitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy,
France, and the United Kingdom), and Japan.
Ulcerative Colitis Pipeline
Ulcerative Colitis Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key ulcerative
colitis companies, including Eli Lilly and Company, Lipid
Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex
Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer
Ingelheim, Janssen Research & Development, Lycera, LG Chem,
Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay
Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio,
Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma,
Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab
Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu
Biologics, PurGenesis Technologies, Protagonist Therapeutics,
Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers
Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular
Transport, AbGenomics International, Protalix BioTherapeutics, LTT
Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation
Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE
Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe
Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio,
Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem,
Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics,
Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences,
Rebiotix, Prometheus Biosciences, PNB Vesper Life Science, Pandion
Therapeutics, Palatin Technologies, Theravance Biopharma,
VHsquared, Seres Therapeutics, Hoffmann-La Roche, Provention Bio,
Bacainn Therapeutics, Landos Biopharma, Bristol-Myers Squibb,
Janssen Research & Development, GlaxoSmithKline, Assembly
Biosciences, NuBiyota, Tarus Therapeutics, Servatus, Athos
Therapeutics, Aclaris Therapeutics, Exeliom Biosciences SAS,
Voronoi Group, Ventria Bioscience, TheraSource LLC, Synlogic Inc,
Synedgen, Surrozen Inc, StemRIM Inc, Shaperon Inc, Sareum Holdings,
Saniona, RhemaStem, Regentys, Progenity, Pharmaxis, Pharmabiome,
PanTheryx, Oncodesign, Nyrada, Microbiotica, MAKScientific,
KoBioLabs, Istesso, Intract Pharma, Innovimmune Biotherapeutics,
Impetis Biosciences, Finch Therapeutics Group, Vivreon Biosciences,
NuMedii, Intact Therapeutics, Giiant Pharma, among
others.
Crohn's Disease Market
Crohn's Disease Market Insights, Epidemiology, and Market
Forecast – 2034 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key Crohn's
disease companies, including Celgene, AstraZeneca, Abbvie,
Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena
Pharmaceuticals, Cytocom, Amgen, Priothera, SLA Pharma, HAV
Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., among
others.
Irritable Bowel Syndrome Market
Irritable Bowel Syndrome Market Insights, Epidemiology, and
Market Forecast – 2034 report delivers an in-depth
understanding of the market trends, market drivers, market
barriers, and key irritable bowel syndrome companies, including
Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston
Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo
Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics,
Biomica, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/skyrizis-approval-for-ulcerative-colitis-treatment-expands-abbvies-portfolio-across-immune-mediated-inflammatory-diseases--delveinsight-302196708.html
SOURCE DelveInsight Business Research, LLP